These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

688 related items for PubMed ID: 30813769

  • 41. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
    Eghtesadi M, Leroux E, Pagé G.
    Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
    [Abstract] [Full Text] [Related]

  • 42. Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
    Suzuki K, Suzuki S, Fujita H, Sakuramoto H, Shioda M, Hirata K.
    Neuropsychopharmacol Rep; 2024 Jun; 44(2):482-484. PubMed ID: 38602109
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T, Noori S, Varakian R, Youssef S, Almadani A.
    BMC Neurol; 2022 Jun 16; 22(1):221. PubMed ID: 35710354
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Medications Approved for Preventing Migraine Headaches.
    Spindler BL, Ryan M.
    Am J Med; 2020 Jun 16; 133(6):664-667. PubMed ID: 32145209
    [Abstract] [Full Text] [Related]

  • 48. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
    Silvestro M, Tessitore A, Scotto di Clemente F, Tedeschi G, Russo A.
    Headache; 2020 Jun 16; 60(6):1187-1195. PubMed ID: 32359106
    [Abstract] [Full Text] [Related]

  • 49. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ.
    Headache; 2018 Nov 16; 58 Suppl 3():238-275. PubMed ID: 30242830
    [Abstract] [Full Text] [Related]

  • 50. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Ashina M, Tepper SJ, Brandes JL, Reuter U, Boudreau GP, Weatherall M, Gantenbein AR, Doležil D, Klatt J, Wang A, Karanam AK, Cheng S, Mikol DD.
    Headache; 2022 May 16; 62(5):624-633. PubMed ID: 35593783
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E, Johnston K, Croop R, Thiry A, Harris L, Powell L, Coric V, L'Italien G, Moren J.
    Headache; 2021 Jun 16; 61(6):906-915. PubMed ID: 34021585
    [Abstract] [Full Text] [Related]

  • 60. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.
    Headache; 2020 Sep 16; 60(8):1734-1742. PubMed ID: 32799325
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.